I am a healthcare professional

Notice


Welcome to MEDICALLY. This website is a non-promotional international resource intended to facilitate transparent scientific exchange regarding developments in medical research and disease management. It is intended for healthcare professionals outside the United Kingdom (UK) and Australia. The content on this website may include scientific information about experimental or investigational compounds, indications and services that are not approved or valid in your jurisdiction. Registration status and prescribing information of medicinal products may differ between countries. Roche and Genentech do not support, endorse or recommend the unapproved use of any compound or service in your jurisdiction, including those discussed on this website.


Please refer to local product information for any medicinal products mentioned. Information available on this website does not constitute professional medical advice, and Roche and Genentech accept no responsibility for access to or use of the same. Healthcare professionals outside the US are required to register and log-in to access the full range of content available on this website.


By clicking on one of the healthcare professional buttons below, you acknowledge you have read and understood this message and that you are requesting access to MEDICALLY. If you are not a healthcare professional, please use the other links below to access information relevant to you.


Cookies


We use cookies on this site to enable the site to function properly and to enhance your user experience. Cookies are files stored in your browser, which most websites use to personalize your web experience. Your information will only be used to provide information that is relevant to you. It will not be used for any other purpose. If you wish to restrict or block cookies, which are set on your device, then you can do this through your browser settings.


You can find out more about cookies by browsing our Privacy Policy.

 

For healthcare professionals in Another Country browse medically.roche.com.

Not a healthcare professional? For individuals outside the US, browse Roche's patient website or roche.com. For individuals in the US, browse gene.com.

External site

By following this link, you are leaving Medically and entering a website that is not owned or controlled by Roche. Roche does not take any responsibility for access to or use of this website, nor for any content therein.

Leave site
Roche and Genentech at

MDS 2022

-
Coming soon

Sign up or login to unlock the full suite of MEDICALLY features

Independent content
Oct 21 / Springer Healthcare
MDS 2022: In-depth report
This MDS 2022 in-depth report provides an overview of advances in the diagnosis and treatment of Parkinson’s disease.

Sign up or login to unlock the full suite of MEDICALLY features

Sep 15 / Roche and Genentech
Exploratory analysis of the effect of delayed-start prasinezumab on motor sign progression measured with the Roche PD Mobile Application v2: PASADENA Phase II Parts 1 and 2
The fluctuating nature of Parkinsonian symptoms make it difficult to measure potential treatment effects from infrequent clinic visit data. The digital health technology (DHT) Roche PD Mobile Application v2 is a smartphone and –watch application enabling remote and frequent assessments of motor signs in individuals with PD. This study aims to determine whether the potential positive effects of prasinezumab, as measured by the Roche PD Mobile Application v2 in the PASADENA Part 1 study, persist in PASADENA Part 2.

Sign up or login to unlock the full suite of MEDICALLY features

Sep 15 / Roche and Genentech
Remote identification of early, sensor based markers of Parkinson's Disease using participants’ smartphones: The Parkinson Progression Marker Initiative Digital sub study
The Parkinson’s Progression Markers Initiative (PPMI) is a longitudinal, observational, multi-centre natural history study containing three main studies: PPMI Online, PPMI Remote, and PPMI Clinical. The PPMI digital sub-study provides a downloadable application for participants for longitudinal monitoring of motor and cognitive signs in PD, as well as passive data collection of motor signs in daily life. This poster summarises the study design of the PPMI digital sub-study and aims to identify the earliest signs and symptoms of PD using remote, at-home assessments with a smartphone application.

Sign up or login to unlock the full suite of MEDICALLY features